Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.
Division of Medical Oncology, Department of Medicine, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, and Seattle Cancer Care Alliance, Seattle, WA.
Ajay K
AK
Gopal
Oncology Division, Department of Medicine, University of Wisconsin-Madison, Madison, WI.
Brad S
BS
Kahl
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Christopher R
CR
Flowers
Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY.
Peter
P
Martin
Division of Hematology, Mayo Clinic, Rochester, MN.
Stephen M
SM
Ansell
Gilead Sciences, Inc., Foster City, CA.
Esteban
E
Abella-Dominicis
Gilead Sciences, Inc., Foster City, CA.
Brian
B
Koh
Gilead Sciences, Inc., Foster City, CA.
Wei
W
Ye
Department of Medicine, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; and.
Paul M
PM
Barr
Department of Hematology, University Claude Bernard Lyon 1, Hospices Civils de Lyon, Pierre-Benite, France.
Gilles A
GA
Salles
Department of Medicine, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; and.
Jonathan W
JW
Friedberg
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D008297:Male; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011687:Purines / Q000008:administration & dosage* / Q000009:adverse effects; D052999:Quinazolinones / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence; D000069283:Rituximab; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D058846:Antibodies, Monoclonal, Murine-Derived; D011687:Purines; D052999:Quinazolinones; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; C552946:idelalisib